GlassScriptPhysician profile
Matthew Edward Facas
NPI 1528630209
$1,331.48
in general payments reported to CMS, 2019-2025
15 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $596 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421.51 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.70 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $221.17 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $124.94 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $82.38 | 2024-2025 | |
| Exact Sciences Corporation | $39.27 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $35.88 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.59 | 2024 | Jardiance |
| Lilly USA, LLC | $34.24 | 2024-2025 | Mounjaro, Zepbound |
| Ibsa Pharma INC. | $31.62 | 2024-2025 | Licart, Tirosint, Flector |
| Dynavax Technologies Corporation | $17.65 | 2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $17.18 | 2025 | |
| Corcept Therapeutics | $16.82 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $15.43 | 2025 | Capvaxive, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $14.10 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Facas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.